No Data
Asia Sheng Pharmaceutical appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors.
Rockville, Maryland and Suzhou, china, November 25, 2024 /PR Newswire/ -- As a leading biomedical company dedicated to developing innovative drugs in areas such as oncology, Ascletis Pharma (6855.HK) announced today the appointment of Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors of the company, effective November 25, 2024. Dr. Yang Dajun, chairman and CEO of Ascletis Pharma, stated: "We warmly welcome Ms. Marina S. Bozilenko and
Talnix BIC's potential recognized by international authoritative journals again, Aegis Medicine-B(06855) milestone developments successively announced boosting market confidence.
On November 22, Ascentage Pharma announced that data from its Phase Ib overseas clinical trial (NCT04260022) on the core product Olverembatinib (trade name: Nalik) for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients has been successfully published in the November 2024 issue of JAMA Oncology, once again reflecting the high recognition of the international hematology community for Olverembatinib as a globally best-in-class potential drug.
Hong Kong stocks unusual movement | Ascentage Pharma-B (06855) up nearly 3%, surpassing the Krysa NDA CED acceptance by force, institutions point to the difficulty of becoming the first domestic drug target.
As of the time of writing, AstraZeneca Pharmaceuticals-B (06855) rose nearly 3%, with an increase of 2.67% to 42.25 Hong Kong dollars, and a turnover of 49.0676 million Hong Kong dollars.
Guosheng Securities: The trend of the domestic innovative drug industry is gradually shifting from license-in to license-out.
Against the backdrop of fierce competition and internal circulation of innovative drug targets in the domestic market, going global is expected to break through the profit ceiling of the domestic market and follow the trend of global innovation.
In half a year, the stock price has doubled, and the commercialization of Asia Sheng Pharmaceutical-B (06855) APG-2575 is imminent, with an expected increase in valuation.
On November 17th, Yasheng health care a announced that the New Drug Application (NDA) for the core variety Bcl-2 inhibitor APG-2575 (proposed Chinese common name: Lisheng Piao) in the company's apoptosis pipeline has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and recommended for priority review, for the treatment of refractory or relapsed (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This undoubtedly marks a key milestone for Yasheng health care a's APG-2575, heralding the official countdown to commercialization of the product.
Express News | Ascentage Pharma Says China's Nmpa Accepts New Drug Application for Co's Novel Bcl-2 Inhibitor Lisaftoclax
No Data
No Data
